BAY 36-7620
Based on 1 Customer Validation
BAY 36-7620 is a potent and noncompetitive antagonist of mGlu1 Receptor (IC50=0.16 μM) with inverse agonist activity. BAY 36-7620 inhibits tumor growth and prolongs the survival of mice with tumors by inhibiting mGlu1 receptor. BAY 36-7620 suppresses AKT phosphorylation in A549 tumors. BAY 36-762 has neuroprotective effect in acute subdural hematoma rat model.BAY 36-7620 is used in non-small cell lung cancer and breast cancer research.
For research use only. We do not sell to patients.
- CAS No.: 232605-26-4
- Formula: C19H18O2
- Molecular Weight:278.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
|
mGluR 1 0.16 μM (IC50) |
mGluR1a 0.38 μM (IC50) |
mGluR2 0.14 μM (IC50) |
mGluR 5 0.24 μM (IC50) |
In Vitro
BAY 36-7620 (0.1-10 μM) completely inhibits mGlu1 receptors 10 μM in HEK 293 Cells[1].
BAY 36-7620 (10-25 μM, 4 days) reduces cell proliferation and inhibits tumor-related protein expression in A549 cells[2].
BAY 36-7620 (72 h) inhibits MCF-7, T-47D, BT-474, MDA-MB-231, Hs578T and BT-549 cell growth and proliferation with IC50s of 27.7, 37.1, 20.8, 41.0, 21.0 and 15.7μM, respectively[3].
BAY 36-7620 (25-50 μM, 24-72 h) causes DNA damage and induces modest G2/M arrest in T-47D, BT-474, MDA-MB-231, and BT-549 cell lines[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 cell line
-
Concentration:10, 25 μM
-
Incubation Time:Overnight
-
Result:Enhanced the expression of cleaved PARP and reduced bcl-2 protein expression.
Reduced the expression of HIF-1α protein and HIF activity.
Reduced the secretion of VEGF and IL-8 into supernatants.
-
Cell Line:T MCF-7, T-47D, BT-474, MDA-MB-231, Hs578T and BT-549 cell line
-
Concentration:50 μM
-
Incubation Time:72 h
-
Result:Decreased the percentage of proliferating cells in all breast cancer cell line.
In Vivo
BAY 36-7620 (0.01-0.03 mg/kg for i.v.; 4 h) has neuroprotective effect in acute subdural hematoma rat model[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lung tumors mice model[2]
-
Dosage:5, 10 mg/kg
-
Administration:Intraperitoneal injection (i.p.); Once daily for 24 days
-
Result:Suppressed tumor growth in athymic mice with lung tumors.
Prolonged the survival of inoculated mice when compared to control group.
Decreased the level of AKT phosphorylation in A549 tumors.
-
Animal Model:Subdural hematoma rat model[4]
-
Dosage:0-3 mg/kg
-
Administration:Intravenous injection (i.v.); 4 h
-
Result:Had neuroprotective effect with the efficacy of 40–50% at 0.01 and 0.03 mg/kg.
Chemical Information
-
CAS No. 232605-26-4
-
Molecular Weight 278.35
-
Formula C19H18O2
-
SMILES
C=C(C1)C[C@@](COC2=O)([H])[C@@]12CC3=CC4=C(C=CC=C4)C=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro:
DMSO : 42 mg/mL (150.89 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Carroll FY, et al. BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol. 2001 May;59(5):965-73. [Content Brief]
[2]. Xia H, et al. Inhibition of metabotropic glutamate receptor 1 suppresses tumor growth and angiogenesis in experimental non-small cell lung cancer. Eur J Pharmacol. 2016 Jul 15;783:103-11. [Content Brief]
[3]. Dolfi SC, et al. Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells. Oncotarget. 2017 Jul 4;8(27):44639-44653. [Content Brief]
[4]. De Vry J, et al. Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620. Eur J Pharmacol. 2001 Oct 5;428(2):203-14. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5926 mL | 17.9630 mL | 35.9260 mL | 89.8150 mL |
| 5 mM | 0.7185 mL | 3.5926 mL | 7.1852 mL | 17.9630 mL | |
| 10 mM | 0.3593 mL | 1.7963 mL | 3.5926 mL | 8.9815 mL | |
| 15 mM | 0.2395 mL | 1.1975 mL | 2.3951 mL | 5.9877 mL | |
| 20 mM | 0.1796 mL | 0.8981 mL | 1.7963 mL | 4.4907 mL | |
| 25 mM | 0.1437 mL | 0.7185 mL | 1.4370 mL | 3.5926 mL | |
| 30 mM | 0.1198 mL | 0.5988 mL | 1.1975 mL | 2.9938 mL | |
| 40 mM | 0.0898 mL | 0.4491 mL | 0.8981 mL | 2.2454 mL | |
| 50 mM | 0.0719 mL | 0.3593 mL | 0.7185 mL | 1.7963 mL | |
| 60 mM | 0.0599 mL | 0.2994 mL | 0.5988 mL | 1.4969 mL | |
| 80 mM | 0.0449 mL | 0.2245 mL | 0.4491 mL | 1.1227 mL | |
| 100 mM | 0.0359 mL | 0.1796 mL | 0.3593 mL | 0.8981 mL |
BAY 36-7620 Related Classifications
HY-107513 Related Classifications
Powered by Bioz